Aridis Pharmaceuticals Inc (NASDAQ:ARDS) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 16,500 shares, an increase of 26.9% from the May 30th total of 13,000 shares. Based on an average trading volume of 4,000 shares, the days-to-cover ratio is currently 4.1 days. Approximately 0.4% of the shares of the company are short sold.
Several equities research analysts recently weighed in on the company. Northland Securities reissued a “buy” rating and issued a $100.00 price objective on shares of Green Dot in a report on Wednesday, April 17th. Zacks Investment Research lowered Green Plains from a “hold” rating to a “strong sell” rating in a report on Thursday, June 27th. Finally, Maxim Group set a $25.00 price objective on Aridis Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 16th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Aridis Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $27.50.
Shares of NASDAQ ARDS opened at $10.00 on Friday. Aridis Pharmaceuticals has a 52 week low of $6.91 and a 52 week high of $13.85. The business has a 50-day moving average of $9.40. The company has a market cap of $81.12 million and a P/E ratio of -1.43.
Aridis Pharmaceuticals (NASDAQ:ARDS) last issued its earnings results on Tuesday, May 14th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.12). Aridis Pharmaceuticals had a negative return on equity of 1,961.31% and a negative net margin of 660.78%. The company had revenue of $1.02 million during the quarter. Sell-side analysts predict that Aridis Pharmaceuticals will post -3.11 EPS for the current fiscal year.
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
See Also: Trading on Margin
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.